Bioventus Inc. $BVS Position Lowered by Knights of Columbus Asset Advisors LLC

Knights of Columbus Asset Advisors LLC lessened its position in shares of Bioventus Inc. (NASDAQ:BVS) by 44.3% in the third quarter, HoldingsChannel.com reports. The fund owned 161,657 shares of the company’s stock after selling 128,688 shares during the period. Knights of Columbus Asset Advisors LLC’s holdings in Bioventus were worth $2,203,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in BVS. Hillsdale Investment Management Inc. boosted its position in shares of Bioventus by 148.7% during the 1st quarter. Hillsdale Investment Management Inc. now owns 671,139 shares of the company’s stock worth $6,128,000 after acquiring an additional 401,230 shares in the last quarter. Engine Capital Management LP acquired a new position in Bioventus during the first quarter valued at approximately $2,876,000. Sei Investments Co. raised its position in Bioventus by 160.7% during the first quarter. Sei Investments Co. now owns 289,648 shares of the company’s stock valued at $2,644,000 after purchasing an additional 178,539 shares in the last quarter. Globeflex Capital L P acquired a new position in Bioventus during the second quarter valued at approximately $1,566,000. Finally, Fifth Third Bancorp bought a new stake in Bioventus during the first quarter worth $1,478,000. Institutional investors own 62.94% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have weighed in on the company. Wall Street Zen downgraded Bioventus from a “strong-buy” rating to a “buy” rating in a report on Saturday, November 7th. Weiss Ratings cut Bioventus from a “buy (b-)” rating to a “hold (c+)” rating in a report on Wednesday, November 4th. Craig Hallum restated a “buy” rating and set a $18.00 price objective on shares of Bioventus in a research report on Thursday, August 6th. Barrington Research set a $18.00 price objective on Bioventus in a research note on Thursday, August 6th. Finally, Canaccord Genuity Group reduced their price objective on Bioventus from $19.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, November 3rd. Five analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $16.60.

Bioventus Trading Down 1.7%

Shares of Bioventus stock opened at $10.99 on Thursday. The firm’s 50 day moving average is $13.28 and its 200 day moving average is $11.01. The firm has a market capitalization of $926.02 million, a PE ratio of 14.33, a price-to-earnings-growth ratio of 1.43 and a beta of 0.66. Bioventus Inc. has a 1 year low of $6.47 and a 1 year high of $15.89. The company has a current ratio of 1.68, a quick ratio of 1.16 and a debt-to-equity ratio of 0.72.

Bioventus (NASDAQ:BVS) last issued its quarterly earnings data on Monday, November 2nd. The company reported $0.17 EPS for the quarter, meeting the consensus estimate of $0.17. The business had revenue of $142.44 million during the quarter. Bioventus had a net margin of 9.78% and a return on equity of 26.31%. Equities research analysts forecast that Bioventus Inc. will post 0.78 earnings per share for the current fiscal year.

About Bioventus

Bioventus Inc. is a medical technology company focused on helping patients recover from musculoskeletal conditions and injuries. Its products and services support bone healing, pain management and surgical care. The company’s offerings include noninvasive devices that use ultrasound to support bone healing, injectable treatments for osteoarthritis pain, and surgical products such as bone graft materials and ultrasonic instruments used in procedures. Bioventus began operations in 2012, originating from businesses previously owned by Smith & Nephew.